5 Apr 2022 , 01:43 PM
Dr Reddys Laboratories announced the launch of Methylprednisolone Sodium Succinate for Injection, USP, the generic equivalent of SOLU-MEDROL? (methylprednisolone sodium succinate for injection, USP) in the U.S. Market approved by the U.S. Food and Drug Administration (USFDA).
The SOLU-MEDROL? brand and generic had U.S. sales of approximately $144 million MAT for the most recent twelve months ending in February 2022 according to IQVIA Health.
Dr. Reddys Methylprednisolone Sodium Succinate for Injection, USP, is supplied in 40 mg/vial,125 mg/vial single-dose vials each carton containing 25 vials; 500 mg and 1 gm multi-dose vial each carton containing 1 vial.
Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
